IntelliPharmaCeutics International (IntelliPharmaCeutics International) COGS-to-Revenue : 0.26 (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International COGS-to-Revenue?

IntelliPharmaCeutics International's Cost of Goods Sold for the three months ended in Aug. 2023 was $0.02 Mil. Its Revenue for the three months ended in Aug. 2023 was $0.07 Mil.

IntelliPharmaCeutics International's COGS to Revenue for the three months ended in Aug. 2023 was 0.26.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. IntelliPharmaCeutics International's Gross Margin % for the three months ended in Aug. 2023 was 73.91%.

IntelliPharmaCeutics International COGS-to-Revenue Historical Data

The historical data trend for IntelliPharmaCeutics International's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International COGS-to-Revenue Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

COGS-to-Revenue

Get a 7-Day Free Trial

0.07

0.01

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	0.26

IntelliPharmaCeutics International COGS-to-Revenue Calculation

IntelliPharmaCeutics International's COGS to Revenue for the fiscal year that ended in Nov. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.066
	=	0.00

IntelliPharmaCeutics International's COGS to Revenue for the quarter that ended in Aug. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.018	/	0.069
	=	0.26

IntelliPharmaCeutics International (OTCPK:IPCIF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

IntelliPharmaCeutics International's Gross Margin % for the three months ended in Aug. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.018 / 0.069
	=	73.91 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

IntelliPharmaCeutics International COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.